GE-backed CardioDx shoots for $86m IPO
This article was originally published in Clinica
Another medtech firm is looking to capitalize on the currently favorable conditions in the public markets to raise some cash. CardioDx, a portfolio company of GE Healthcare that is developing noninvasive gene expression tests to help doctors better assess and treat patients with cardiovascular diseases, is looking to raise up to $86.3m in its IPO. It did not disclose how many shares it hopes to sell or at what price. If successful, it will list on the Nasdaq under the ticker symbol CDX.